Friday 6 November 2026 Export PEN’s income statement to Excel — free account

Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue: +15.6%
EPS: −8.29%
Free cash flow: −37.2%
Total debt: −10.3%

Quarter to September 2026, against a year earlier

320.08 1.03 −0.32%

Follow PEN

Alert me

Market cap: $12.7B
P/E: 80.3×
Fwd P/E: 68.7×
Dividend yield: —
F-score: 8/9
Altman Z: 20.17
Beneish M: −2.48
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Penumbra, Inc. (PEN) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Penumbra, Inc. (PEN) trades at a P/S ratio of 8.1×. Over the past ten years it has ranged from 0.0× (September 2015) to 19.1× (April 2021); the current reading is higher than 28% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PEN/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Penumbra, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PEN/metrics/ps-ratio">Penumbra, Inc. (PEN) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	8.6×	12.24%
FY2024	7.7×	(13.51%)
FY2023	8.9×	(10.13%)
FY2022	9.9×	(30.07%)
FY2021	14.1×	26.51%
FY2020	11.2×	7.10%
FY2019	10.4×	11.23%
FY2018	9.4×	5.03%
FY2017	8.9×	20.47%
FY2016	7.4×	113.69%

Period	P/S ratio	Change
Sep 2026	8.0×	(2.64%)
Jun 2026	8.3×	(6.89%)
Mar 2026	8.9×	2.87%
Dec 2025	8.6×	16.15%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 19.1×

Ten-year median 9.4×

Current reading's percentile 21

Company	P/S ratio
SNN Smith & Nephew SNATS, Inc. compare	1.4×
BRKR Bruker Corporation compare	2.5×
PODD Insulet Corporation compare	3.4×
GMED Globus Medical, Inc. compare	3.5×
BIO Bio-Rad Laboratories, Inc. compare	3.8×
BIO.B Bio-Rad Laboratories, Inc. compare	3.9×
PEN Penumbra, Inc.	8.1×
TXG 10x Genomics compare	12.4×
GKOS Glaukos Corporation compare	18.8×
Medical Devices industry median	2.5×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Penumbra, Inc. (PEN) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PEN

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PEN

Stockrow Weekly